

Local Anaesthetic Systemic Toxicity

© Department for Health and Wellbeing, Government of South Australia. All rights reserved.

Note:

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve, or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient's medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate, and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements, and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements.

Note: The words woman/women/mother/she/her have been used throughout this guideline as most pregnant and birthing people identify with their birth sex. However, for the purpose of this guideline, these terms include people who do not identify as women or mothers, including those with a non-binary identity. All clinicians should ask the pregnant person what their preferred term is and ensure this is communicated to the healthcare team.



The term Aboriginal is used respectively in this document as an all-encompassing term for Aboriginal and Torres Strait Islander people and culture.



Australian Aboriginal Culture is the oldest living culture in the world yet Aboriginal people continue to experience the poorest health outcomes when compared to non-Aboriginal Australians. In South Australia, Aboriginal women are 2–5 times more likely to die in childbirth and their babies are 2–3 times more likely to be of low birth weight. The accumulative effects of stress, low socio-economic status, exposure to violence, historical trauma, culturally unsafe and discriminatory health services, and health systems are all major contributors to the disparities in Aboriginal maternal and birthing outcomes. Despite these unacceptable statistics, the birth of an Aboriginal baby is a celebration of life and an important cultural event bringing family together in celebration, obligation, and responsibility. The diversity between Aboriginal cultures, language and practices differ greatly and so it is imperative that perinatal services prepare to respectfully manage Aboriginal protocol and provide a culturally positive health care experience for Aboriginal people to ensure the best maternal, neonatal and child health outcomes.


Explanation of the Aboriginal artwork: The Aboriginal artwork used symbolises the connection to country and the circle shape shows the strong relationships amongst families and the Aboriginal culture. The horseshoe shape design shown in front of the generic statement symbolises a woman and those enclosing a smaller horseshoe shape depicts a pregnant woman. The smaller horseshoe shape in this instance represents the unborn child. The artwork shown before the specific statements within the document symbolises a footprint and demonstrates the need to move forward together in unison.

Purpose and Scope of PPG

The purpose of this guideline is to give clinicians information on the signs of local anaesthetic systemic toxicity (LAST) with subsequent management and follow up care.



Flowchart 1| Immediate Management of Local Anaesthetic Systemic Toxicity (LAST)



Local Anaesthetic Systemic Toxicity PPG v5.0 (17/03/2025)

Reference: Association of Anaesthetists 2023. Quick Reference Handbook Available from: <https://anaesthetists.org/quick-reference-handbook> (also see [QRH 3-10 Local anaesthetic toxicity v2 June 2023.pdf \(anaesthetists.org\)](#))¹

For a printable version see [Appendix 1](#)

Local Anaesthetic Systemic Toxicity

Table 1| Weight Specific Intralipid Regime

	Immediately		At 5 and 10 minutes if:	At any time after 5 minutes if:			
			- cardiovascular stability not restored or				
			- an adequate circulation deteriorates				
Weight	Initial Bolus		Initial Infusion	Repeat bolus (same dose)	Increased infusion	Maximum	
	1.5mL/kg over 2 - 3 minutes		Start at 15mL/kg	Same dose (can be repeated)	Increase infusion to 30mL/kg/h	12mL/kg	
Kilograms	mL	mL/hr over 3 minutes	mL/hr	mL	mL/hr over 3 minutes	mL/hr	mL
40	60	1200	600	60	1200	1200	480
45	67.5	1350	675	67.5	1350	1350	540
50	75	1500	750	75	1500	1500	600
60	90	1800	900	90	1800	1800	720
70	105	2100	1050	105	2100	2100	840
80	120	2400	1200	120	2400	2400	960
90	135	2700	1350	135	2700	2700	1080
100	150	3000	1500	150	3000	3000	1200

Note:

- More than one infusion pump may be needed for rates > 1200 mL/hour
- Individual services should check the maximum infusion rates of the pumps that they have available for administering intralipid.
- If the pumps available have a maximum infusion rate below the rates in the table, a risk assessment of using additional methods to the use of one pump for intralipid administration should be considered.

Local Anaesthetic Systemic Toxicity

Table of Contents

Purpose and Scope of PPG	1
Flowchart 1 Immediate Management of Local Anaesthetic Systemic Toxicity (LAST)	2
Table 1 Weight Specific Intralipid Regime.....	3
Table of Contents	4
Summary of Practice Recommendations	5
Abbreviations	5
Definitions	6
Introduction	6
Immediate Management of Local Anaesthetic Systemic Toxicity	6
Recognise: Signs of Severe Toxicity	6
Respond and Escalate	6
Control Seizures: Pharmacological Management	7
Management of LAST in Cardiac Arrest.....	7
Management of LAST Without Cardiac Arrest	7
Follow-up	8
Resources.....	9
References	9
Bibliography.....	9
Appendix 1 Local Anaesthetic Toxicity Pharmacological Management Printable Poster	10
Acknowledgements	11
Write Group Lead	11
Write Group Members	11
Major Contributors	11
SAPPG Management Group Members	11
Document Ownership & History	12



Local Anaesthetic Systemic Toxicity

Summary of Practice Recommendations

Local anaesthetic system toxicity (LAST) is a medical emergency. Early recognition and prompt escalation and response is vital.

Signs of LAST do not always appear immediately post initial injection.

Signs may include:

- sudden alteration in mental status, severe agitation or, sudden loss of consciousness with or without tonic-clonic convulsions
- Cardiovascular collapse, sinus bradycardia, conduction blocks asystole and ventricular tachyarrhythmia may all occur.

Stop the administration of local anaesthetic immediately at first signs of LAST.

Call for help as per local health network protocol.

Resuscitate following the Basic Life Support (BLS) and Advanced Life Support (ALS) algorithms found in *Maternal Collapse PPG* found in the A-to-Z listing at www.sahealth.sa.gov.au/perinatal.

Give **intravenous 20% lipid emulsion** as per [flowchart 1](#).

Note: Benzodiazepines, thiopentone, propofol and neuromuscular blocking drugs **must only** be administered by a practitioner familiar with the use of these drugs and has advanced airway skills, or with an additional practitioner confident in these skills immediately available at the bedside.

Recovery from local anaesthetic induced cardiac arrest may take longer than an hour. Continue resuscitation efforts for this time.

Abbreviations

>	Greater than
≥	Equal to or greater than
<	Less than
≤	Equal to or less than
ALS	Advanced life support
BLS	Basic life support
DR S ABC	Danger, response, send for help, airway, breathing, circulation
g	Gram(s)
IV	Intravenous
kg	Kilogram
LAST	Local anaesthetic systemic toxicity
MET	Medical emergency team
mg	Milligram(s)
mg/kg	Milligram per kilogram
mL	Millilitre(s)
Microg	Microgram(s)



Local Anaesthetic Systemic Toxicity

Definitions

Local anaesthetic toxicity	A potentially fatal complication of regional anaesthesia. It can also occur in other situations with local anaesthetic injections.
Shared decision making	Shared decision making involves discussion and collaboration between a consumer and their healthcare providers. It is about bringing together the consumer's values, goals, and preferences with the best available evidence about benefits, risks and uncertainties of screening, investigations, and treatment, to reach the most appropriate healthcare decisions for that person.

Introduction

Local anaesthetic systemic toxicity (LAST) is a rare and potentially fatal complication that occurs in some instances where regional anaesthesia is used. Toxicity from local and infiltration anaesthetics can be either localised (neurovascular) or systemic (affecting the central nervous or cardiovascular systems).²

Signs of LAST do not always occur immediately after the initial injection. In some cases the onset of symptoms can be delayed up to several minutes.³ It is therefore imperative to regularly monitor for signs of toxicity post anaesthetic administration.

Immediate Management of Local Anaesthetic Systemic Toxicity

Recognise: Signs of Severe Toxicity

Central Nervous System:

- sudden alteration in mental status
- severe agitation or
- sudden loss of consciousness with or without tonic-clonic convulsions.⁴

Cardiovascular System:

- cardiovascular collapse
- sinus bradycardia
- conduction blocks
- asystole and
- ventricular tachyarrhythmia may all occur.⁴

Respond and Escalate

Local anaesthetic systemic toxicity is an emergency.

Stop administering local anaesthetic, including infusions **immediately.**

Call for Help: state '**local anaesthetic toxicity**'

- Activate medical emergency team (Code Blue or MET call), or senior medical support, including anaesthetists as per local health network protocol.
- Commenced emergency management response:
 - follow basic life support (DR S ABC) and advanced life support algorithms as per the *Maternal Collapse PPG* found in the A-to-Z listing at www.sahealth.sa.gov.au/perinatal



Local Anaesthetic Systemic Toxicity

- **Give 100% oxygen** and ensure adequate lung ventilation:
 - consider an endotracheal tube to maintain and secure the airway
 - avoid hypoxia and hypercarbia as both conditions worsen LAST.
- Confirm or establish **intravenous access**.⁵

Control Seizures: Pharmacological Management



Important: Benzodiazepines, thiopentone, propofol and neuromuscular blocking drugs **must** only be administered by a practitioner familiar with the use of these drugs and has advanced airway skills, or with an additional practitioner confident in these skills immediately available at the bedside.

First line:

Give small incremental doses of a benzodiazepine:

- **Midazolam (IV) 0.1–0.2 mg/kg, slow bolus** (i.e., 5 mg over two minutes or 10 mg over four minutes)

Second line (if seizures do not end):

- **Propofol (IV), 20 mg increments (titrated to effect)**
 - Use with caution.
 - Give small incremental doses.
 - Note the negative inotropic effects of propofol (and thiopentone).⁵
 - Monitor cardiovascular status closely.
- Consider neuromuscular blockade if seizures cannot be controlled, to avoid worsening acidosis from muscle activity (this will not affect cerebral activity).
- Consider drawing blood for analysis, but **do not** delay definitive treatment to do this.

Management of LAST in Cardiac Arrest

- Commence **cardiopulmonary resuscitation (CPR)** immediately.
 - See *Maternal Collapse PPG* found in the A-to-Z listing at www.sahealth.sa.gov.au/perinatal.
- Give **intravenous 20% lipid emulsion** as per [flowchart 1](#).
 - Doses based on body weight (see [Table 1](#))
 - **Do not** exceed maximum cumulative dose of 12 mL/kg.
 - In circumstances where high lipid emulsion infusion rates are required (e.g., 2000 mL/hr) and volumetric pumps to deliver these amounts, then consider using two pumps simultaneously to deliver the required amount.
- **Continue CPR** throughout treatment with lipid emulsion.
 - Consider the use of cardiopulmonary bypass if available.
 - Use smaller doses of adrenaline (i.e., give ≤ 1 microg/kg instead of 1 mg), to prevent afterload and impairing pulmonary flow.
 - Manage arrhythmias, recognising that arrhythmias may be refractory to treatment.
- Recovery from local anaesthetic induced cardiac arrest may take more than 1 hour.
- **Consider** perimortem caesarean section by 5 minutes post cardiac arrest in pregnant women beyond 24 weeks gestation as per *Maternal Collapse PPG* found in the A-to-Z listing at www.sahealth.sa.gov.au/perinatal.

Management of LAST Without Cardiac Arrest

- Strongly consider **intravenous 20% lipid emulsion** treatment (see [flowchart 1](#)).



Local Anaesthetic Systemic Toxicity

- It is difficult to predict which patients will progress to cardiovascular collapse, but lipid emulsion is a low-risk intervention that may prevent this deterioration.
- Doses are based on body weight.
- **Do not** exceed maximum cumulative dose of 12 mL/kg.
- in circumstances where high lipid emulsion infusion rates are required (e.g., 2000 mL/hr) and volumetric pumps to deliver these amounts, then consider using two pumps simultaneously to deliver the required amount.
- Propofol is **not** a suitable substitute for lipid emulsion.
- Use conventional therapies to treat:
 - **Hypotension**
 - Avoid vasopressin.
 - **Bradycardia**
 - Consider atropine as first line.
 - **Tachyarrhythmia**
 - Consider amiodarone as first line.
 - Avoid beta-blockers, calcium channel antagonists and lidocaine (lignocaine), and other class 1 anti-arrhythmic (e.g., quinidine, procainamide, mexiletine).
- Hypoxia, hypercarbia, and acidosis worsen the negative inotropy seen in LAST, but it is unclear whether the risks of alkalinising a profoundly acidotic patient outweigh the benefits.
 - Sodium bicarbonate and significant hyperventilation **is not** recommended.
- Methemoglobinemia may rarely be associated with LAST, when the toxicity is caused by lignocaine and prilocaine.

Follow-up

- Arrange safe transfer to a clinical area with appropriate equipment and suitable staff is available until sustained recovery is achieved.
- Once stable:
 - post seizure: observe for 2 hours
 - post cardiovascular instability: observe for 4–6 hours
 - post cardiac arrest: as per senior medical advice.
- Side effects of lipid emulsion are rare but include pancreatitis and deep vein thrombosis.
 - Consider thromboprophylaxis (See *Thromboprophylaxis and Thromboembolic Disease in Pregnancy PPG* found in the A-to-Z listing at www.sahealth.sa.gov.au/perinatal).
 - Assays for amylase and lipase are unreliable in the diagnosis of pancreatitis.
 - Lipid emulsion may interfere with filters used for renal replacement therapy and may cause fat deposition and blood clots in cardiopulmonary bypass, and extracorporeal membrane oxygenator circuits.
- Notify hospital management in accordance with local clinical governance guidelines and complete a safety learning system (SLS) notification (see [Safety Learning System | SA Health](#)).
- Document events and debrief as per *Maternal Collapse PPG* found in the A-to-Z listing at www.sahealth.sa.gov.au/perinatal.



Resources

SAPPGs Web-based App:

[Practice Guidelines \(sahealth.sa.gov.au\)](https://sahealth.sa.gov.au)

Medicines Information: (sahealthlibrary.sa.gov.au)

<https://sahealthlibrary.sa.gov.au/friendly.php?s=SAPharmacy>

SA Health Pregnancy:

[Pregnancy | SA Health](#)

Australian Government Pregnancy, Birth and Baby: (www.pregnancybirthbaby.org.au)

[Pregnancy, Birth and Baby | Pregnancy Birth and Baby \(pregnancybirthbaby.org.au\)](#)

Pathology Tests Explained: (<https://pathologytestsexplained.org.au/>)

[Pathology Tests Explained](#)


References

1. Association of Anaesthetists. 3-10 Local anaesthetic toxicity. 2023. In: Quick reference handbook: Guidelines for crises in anaesthesia [Internet]. Online: Association of Anaesthetists. Available from: https://anaesthetists.org/Portals/0/PDFs/QRH/QRH_3-10_Local_anaesthetic_toxicity_v2_June%202023.pdf?ver=2023-06-23-141010-760.
2. Sheppard HN, Anandampillai R. Systemic toxic effects of local anaesthetics. *Anaesthesia & Intensive Care Medicine*. 2019;20(4):215-8.
3. Lago E, Angeli V, Dedato AS, Santaniello A, Perlini S, Di Pietro S, et al. Local anaesthetic toxicity syndrome: can posters illustrating the treating algorithm improve medical management? *Internal and Emergency Medicine*. 2023;18(7):2149-50.
4. Warren L, Pak A. Local anesthetic systemic toxicity. 2024 [cited 26th April 2023]. In: Up To Date [Internet]. Online: Wolters Kluwer, [cited 26th April 2023]. Available from: <https://www.uptodate.com/contents/local-anesthetic-systemic-toxicity>.
5. Macfarlane A, Gitman M, Bornstein K, El-Boghdady K, Weinberg G. Updates in our understanding of local anaesthetic systemic toxicity: a narrative review. *Anaesthesia*. 2021;76:27-39.

Bibliography

- Blumenberg A. Could alkalinization worsen local anesthetic systemic toxicity? *American Journal of Emergency Medicine* 2022; 58:342-344
- Christie LE et al. Local anaesthetic systemic toxicity. *British Journal of Anaesthesia Education* 2015;15(3):136-142.
- McMahon K, Paster J, Baker KA. Local anesthetic systemic toxicity in the pediatric patient. *American Journal of Emergency Medicine* 2022; 54:325.e3–325.e6
- Neal JM et al. The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity Executive Summary 2017. *Regional Anesthesia & Pain Medicine* 2018;43(2):113-123
- Neal JM, Neal EJ, Weinberg GL. American Society of Regional Anesthesia and Pain Medicine Local Anesthetic Systemic Toxicity checklist 2020 version. *Regional Anesthesia & Pain Medicine* 2021;46:81-82.





***Do Not exceed maximum cumulative dose of 12 mL/kg of 20% lipid emulsion**

See table 1 for weight-based dosing of intralipid.

Local Anaesthetic Systemic Toxicity PPG v5.0 (17/03/2025)

Reference: Association of Anaesthetists 2023. Quick Reference Handbook Available from: <https://anaesthetists.org/quick-reference-handbook> (also see [QRH 3-10 Local anaesthetic toxicity v2 June 2023.pdf \(anaesthetists.org\)](#))

Local Anaesthetic Systemic Toxicity

Acknowledgements

The South Australian Perinatal Practice Guidelines gratefully acknowledge the contribution of clinicians and other stakeholders who participated throughout the guideline development process particularly:

Write Group Lead

Dr Charlotte Wade
Dr Charlotte Taylor

Write Group Members

Dr Kym Osborn
Dr Haran Somehsa
Dr Kylie Stanton

Major Contributors

Dr Michael McEvoy
Dr Danielle Crosby

SAPPG Management Group Members

Dr Michael McEvoy (Chair)
Monica Diaz (SAPPG EO)
Dr Elizabeth Allen
Elise Bell
Dr Angela Brown
Marnie Campbell
John Coombas
Dr Danielle Crosby
Imogen Downard John
Kate Greenlees
Luke Grzeskowiak
Kathryn Hansen
Dr Gemma Hardi
Dr Susie Keynes
Belinda Nitschke
Dr Angela Mathew
Dr Scott Morris
Dr Amanda Poprzeczny
Dr Anthia Rallis
Amy Rigano
Dr Shruti Tiwari
Sally Wadsworth
Allison Waldron



Local Anaesthetic Systemic Toxicity

Suggested citation:

Wade C, Taylor C. Local Anaesthetic Systemic Toxicity [Internet]. Version 5. Adelaide (AU): South Australian Perinatal Practice Guideline; SA Health, Government of South Australia; 2025. 12 p. Guideline No.: PPG253. Available from: <http://www.sahealth.sa.gov.au/perinata>

OFFICE USE ONLY

Document Ownership & History

Developed by:	Maternal, Neonatal and Gynaecology Strategic Executive Leadership Committee
Contact:	HealthCYWHSPerinatalProtocol@sa.gov.au
Approved by:	Clinical Guidelines Domain Custodian
Next review due:	17/03/2030
CGSQ reference:	PPG253
Guideline history:	<p>Is this a new perinatal practice guideline (V1)? N</p> <p>Does this perinatal practice guideline amend or update an existing perinatal practice guideline? Y</p> <p>If so, which version? 4.1</p> <p>Does this perinatal practice guideline replace another perinatal practice guideline or policy with a different title? N</p> <p>If so, which perinatal practice guideline or policy (title)?</p>

Approval date	Version	Who approved new/revised version	Reason for change
17/03/2025	V5.0	Clinical Guideline Domain Custodian	Formally reviewed in line with 5-yearly scheduled timeline for review. Title changed.
14/05/2020	V4.1	Chair, SA Maternal, Neonatal & Gynaecology Community of Practice	Re-templated, risk assessed and extended for 2 years.
06/03/2017	V4.0	SA Health Safety and Quality Strategic Governance Committee	Reviewed
01/02/2010	V3.0	SA Maternal and Neonatal Clinical Network	Minor update
25/01/2010	V2.0	SA Maternal and Neonatal Clinical Network	Reviewed
09/06/2009	V1.0	SA Maternal and Neonatal Clinical Network	Original SA Maternal and Neonatal Clinical Network approved version

